Portfolio Expansion Journey Medical markets seven branded and two generic dermatology products, presenting cross-selling opportunities with clinics and wholesalers focused on skin conditions and rosacea, enabling targeted bundling and co-promotions with Emrosi and existing brands.

Public Market As a Nasdaq-listed, commercial-stage company with ongoing conference appearances and a leadership team, there are notable visibility and credibility signals to engage potential larger healthcare partners, distributors, and contract manufacturers seeking established dermatology portfolios.

Growth Milestones Recent launch of Emrosi for rosacea and four-year public trading history highlight momentum and a track record of commercial execution, providing a compelling case for partnerships around expansion into additional dermatology indications and patient access programs.

Leadership Access Executive appointments and board additions (CFO promotion, new director) indicate strong governance and financial discipline, facilitating conversations with investors, lenders, and strategic buyers about scalable commercial partnerships and alongside potential co-development deals.

Market Positioning Active engagement in industry conferences and dermatology-focused events suggests demand for strategic collaborations, distribution agreements, and clinical-focused marketing initiatives to accelerate penetration in U.S. dermatology channels and specialty clinics.